[Result of phase II clinical trial of herceptin in advanced Chinese breast cancer patients].
OBJECTIVE
To observe the clinical efficacy and adverse effects of herceptin for advanced Chinese breast cancer patients.


METHODS
Thirty-one pathologically proved advanced breast cancer women were treated by herceptin. In the first week, a loading dose 4 mg/kg was administered by intravenous infusion and from the second week, a routine dose of 2 mg/kg was given every week for at least 3 months.


RESULTS
There were 2 CR, 6 PR, 7 SD, and 16 PD among 31 patients after treatment by herceptin, the response rate being 25.8%. In factors influencing the prognosis, age and general condition were factors favoring the results, and pathological type, site of metastasis, grade of her-2 over expression and prior treatment were irrelevant to the results. The adverse effects were mild but different from those of the common anticancer drugs.


CONCLUSIONS
Herceptin is effective and well tolerated by the Chinese breast cancer patients.
Sun
Yan
Y
Department of Medical Oncology, Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China.
Li
Li-qing
LQ
Song
San-tai
ST
Xu
Li-gong
LG
Yu
Shi-ying
SY
Wang
Jin-wan
JW
Jiang
Ze-fei
ZF
Yin
Ji-liang
JL
Xiong
Hui-hua
HH
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068878:Trastuzumab